Drug intelligence / Profile preview

decitabine + TQB2450 + anlotinib

Development stage: Unknown
Lead developer: Chia Tai-Tianqing Pharmaceutical Group
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous, Oral

Overview

A combination therapy consisting of decitabine, TQB2450 (benmelstobart), and anlotinib. TQB2450 is a humanized monoclonal antibody targeting PD-L1, while anlotinib is a multi-targeted tyrosine kinase inhibitor that inhibits VEGFR2/3, FGFR1-4, PDGFR-α/β, c-Kit, and Ret. Decitabine is a DNA methyltransferase inhibitor. This combination aims to leverage immune checkpoint inhibition, anti-angiogenic effects, and hypomethylating activity for cancer treatment.

Targets

CSF1R (Macrophage colony-stimulating factor receptor)AURKB (Aurora kinase B)FGFR3 (Fibroblast growth factor receptor 3)PDGFRA (Platelet-derived growth factor receptor alpha)VEGFR4 (Vascular endothelial growth factor Receptor-3)DNMT1 (DNA (cytosine-5)-methyltransferase 1)KIT (c-KIT proto-oncogene receptor tyrosine kinase)VEGFR-1 (Vascular endothelial growth factor receptor 1)CD274 (Programmed cell death protein 1 ligand 1)VEGFR2 (Vascular endothelial growth factor receptor 2)RET (Rearranged during transfection receptor tyrosine kinase)DDR1 (Discoidin domain receptor 1)

Beyond the preview

Go deeper on decitabine + TQB2450 + anlotinib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on decitabine + TQB2450 + anlotinib.

Explore the full profile